TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05598840

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Care for today Mobile Application
Description: C4T (Care for Today) Education is a digital application (app) designed to offer quality educational materials.~The APP will be provided to the patients in the outpatient centre four months before surgery. Patients will be able to download the APP using a QR code that will be provided during the visit. They'll realize the download immediately or at home, in both cases a detailed explication of how to use the APP and its contents will be provided using an example version.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Care for today Mobile Application
Description: C4T (Care for Today) Education is a digital application (app) designed to offer quality educational materials.~The APP will be provided to the patients in the outpatient centre four months before surgery. Patients will be able to download the APP using a QR code that will be provided during the visit. They'll realize the download immediately or at home, in both cases a detailed explication of how to use the APP and its contents will be provided using an example version.
Study: NCT05445206

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CardioPulmonary Management Device (CPM)
Description: CPM device is used in tangent with reference capnography device.
Study: NCT05388773

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Transoral surgical resection of tumor(s).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Transoral surgical resection of tumor(s).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Transoral surgical resection of tumor(s).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: intensity-modulated radiation therapy
Description: Low-dose IMRT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: intensity-modulated radiation therapy
Description: Low-dose IMRT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV
Study: NCT06102356

Intervention type: OTHER
Intervention: Questionnaire
Description: DLQI TSQM v.II PHQ-9 DS14
Study: NCT06455410

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GP
Description: gemcitabine + cisplatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GP
Description: gemcitabine + cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebrelimab
Description: a PD-L1 inhibitor
Study: NCT05845970

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pamprin Botanicals
Description: Participants will take Pamprin Botanicals only. Participants will take 450mg of Pamprin Botanicals two days before their predicted period and then take it every day during their period. Participants can also take Pamprin Botanicals two days after the bleeding has concluded.
Study: NCT06455410

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: concurrent chemoradiotherapy (CCRT)
Description: concurrent chemoradiotherapy (CCRT)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: concurrent chemoradiotherapy (CCRT)
Description: concurrent chemoradiotherapy (CCRT)
Study: NCT05845970

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Pamprin Botanicals + Pamprin Menstrual Pain Relief
Description: Participants will repeat taking Pamprin Botanicals two days before their second predicted period and continue to take it each day during their period. However, during the second period, participants will also take Pamprin Menstrual Pain Relief per the over-the-counter directions (2 tablets every 6 hours with water).
Study: NCT04815291

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Receives SCOUT at biopsy
Description: SCOUT Reflector
Study: NCT05299411

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: iron (isomaltoside)
Description: iron supplement through intravenous infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dried Ferrous Sulfate
Description: iron supplement through oral intake
Study: NCT06110962

Intervention type: DEVICE
Intervention: Sleeptracker-AI
Description: The Sleeptracker-AI Monitor (Fullpower Technologies, California, USA) is a commercially available, unobtrusive, and non-wearable home sleep monitoring device. It is either pre-installed in a mattress or can be purchased separately by consumers where it is placed under the mattress. The device uses piezo-electric sensors that register the forces exerted through the mattress by features such as the subject's motion, respiration, heartbeats, and snoring vibrations.
Study: NCT05285124

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: Participants assigned to the melatonin group were given a 3-mg fast-release oral dose of melatonin administered at approximately 21:00

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: Participants assigned to the melatonin group were given a 3-mg fast-release oral dose of melatonin administered at approximately 21:00

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants in this group were treated according to a protocol identical to those receiving active medication at approximately 21:00. For the sham tDCS groups, the same stimulation parameters were employed, except that the stimulator had a built-in placebo mode; when it was activated, two ramp fade-in/fade-out periods in the beginning and the end of sham stimulation mimicked the somatosensory artifact of real tDCS

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants in this group were treated according to a protocol identical to those receiving active medication at approximately 21:00. For the sham tDCS groups, the same stimulation parameters were employed, except that the stimulator had a built-in placebo mode; when it was activated, two ramp fade-in/fade-out periods in the beginning and the end of sham stimulation mimicked the somatosensory artifact of real tDCS

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HD-tDCS
Description: Direct current was applied using a battery-driven constant-current stimulator through saline-soaked surface sponge electrodes (7cm×5cm) with the anode placed over the left DLPFC (F3 according to the 10-20 international EEG system) and the reference cathode placed over the right supraorbital region (Fp2). During real tDCS, the current was increased to 2 mA from the onset of stimulation and applied for 20 minutes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HD-tDCS
Description: Direct current was applied using a battery-driven constant-current stimulator through saline-soaked surface sponge electrodes (7cm×5cm) with the anode placed over the left DLPFC (F3 according to the 10-20 international EEG system) and the reference cathode placed over the right supraorbital region (Fp2). During real tDCS, the current was increased to 2 mA from the onset of stimulation and applied for 20 minutes
Study: NCT05762861

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental
Description: Patients will be every two weeks monitored by the researchers' team, taking into consideration lung function, symptoms, physical activity, pulse oximetry, body temperature, need for relief medication and Sputum characteristics. Over the 18 months, they will be the target of health education interventions, 2 individual and 2 in group.
Study: NCT05347940

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mirror therapy
Description: A Mirror box will be used to easily create illusion. It' is a box with one mirror in the center where on each side of it, the hands are placed in a manner that the affected limb is kept covered always and the unaffected limb is kept on the other side whose reflection can be seen on the mirror.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: traditional physiotherapy protocol for flexor tendon repair
Description: include stretching exercises and active ROM exercises
Study: NCT06214052

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VH4524184
Description: VH4524184 will be administered.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered.
Study: NCT05764668

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zihua Wenfei Zhisou Granule
Description: 14 daily- doses of Zihua Wenfei Zhisou Granule，one bag at a time (15 g/bag), three times/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 14 daily- doses of placebo，one bag at a time (15 g/bag), three times/day
Study: NCT05373628

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Gradient and pulse imaging
Description: A novel diffusion-based magnetic resonance imaging method
Study: NCT06301048

Intervention type: PROCEDURE
Intervention: Stent Placement in Pancreatic and Bile Ducts
Description: Post-resection, endoscopic retrograde cholangiopancreatography (ERCP) was performed for stent placement in pancreatic or bile ducts as needed, with X-ray confirmation of stent positioning.

Intervention type: PROCEDURE
Intervention: Stent Placement in Pancreatic and Bile Ducts
Description: Post-resection, endoscopic retrograde cholangiopancreatography (ERCP) was performed for stent placement in pancreatic or bile ducts as needed, with X-ray confirmation of stent positioning.
Study: NCT05826496

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The supervised high-intensity interval training is conducted on bicycle ergometers at 85-95% maximal workload. The high-intensity interval sequences will be separated by two steady state sequences. Blood samples are collected at baseline, 2 min and 60 min post-exercise.
Study: NCT05314530

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ReTA-model
Description: Validating the rehabilitation model ReTA

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ReTA-model
Description: Validating the rehabilitation model ReTA
Study: NCT04625530

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ferric carboxymaltose
Description: Ferric carboxymaltose 20 mg/kg (with a maximum dose of 1000 mg ferric carboxymaltose in a single Infusion) (Ferinject® 1000 mg/20ml, Vifor (International) AG, St. Gallen, Switzerland) will be diluted in 250 ml of 0.9% m/V sodium chloride solution and administered over 15 minutes intravenously between day -27 and day -7. The colour of ferric carboxymaltose is dark brown. A single Ferinject administration should not exceed 20 mg iron/kg body weight.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tranexamic acid
Description: Tranexamic acid 10mg/kg (Tranexam OrPha 1000 mg/10 ml, OrPha Swiss GmbH, Küsnacht, Switzerland) will be administered 15 -30 minutes prior to surgery followed by infusion of tranexamic acid through syringe pump (1 mg/kg/h) till 4 h postoperatively. The colour of the medicament is transparent.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ferric carboxymaltose and tranexamic acid
Description: Ferric carboxymaltose (Ferinject® 1000 mg/20 ml) will be administered between day -27 and day -7 and tranexamic acid (Tranexam OrPha 1000 mg/10 ml) 15-30 minutes prior to surgery followed by infusion of tranexamic acid through syringe pump (1 mg/kg/h) till 4 h postoperatively.
Study: NCT05537636

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabiltiation using exercise and manual therapy
Description: A licensed Physical Therapist will provide manual therapy to help restore spinal and scapular mobility. In association with this patients will be prescribed home exercises using a phased approach.~Phase 1 to gain mobility of the spine and scapular motor control Phase 2 to gain shoulder mobility to strengthen scapular and spine musculature Phase 3 shoulder strengthening with long lever arms.
Study: NCT04909892

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVI-MSC
Description: COVI-MSC are allogeneic culture-expanded adipose-derived mesenchymal stem cells

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVI-MSC
Description: COVI-MSC are allogeneic culture-expanded adipose-derived mesenchymal stem cells
Study: NCT05079750

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAdOx1 biEBOV
Description: ChAdOx1 biEBOV provided as a liquid in glass vials and administered intramuscularly into the deltoid of the non-dominant arm (preferably)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAdOx1 biEBOV
Description: ChAdOx1 biEBOV provided as a liquid in glass vials and administered intramuscularly into the deltoid of the non-dominant arm (preferably)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAdOx1 biEBOV
Description: ChAdOx1 biEBOV provided as a liquid in glass vials and administered intramuscularly into the deltoid of the non-dominant arm (preferably)
Study: NCT05599451

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: THS Blade device
Description: Tobacco Heating System (THS) device with Blade technology for Blade tobacco stick use

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: THS Induction Mono device
Description: Tobacco Heating System (THS) device with Induction technology (combined Charger-Holder device for Induction tobacco stick use).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: THS Induction Mid device
Description: Tobacco Heating System (THS) device with Induction technology (device with Induction stick Holder for Induction tobacco stick use and separate Charger).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CIG
Description: Subject's preferred brand of commercially available regular (non-mentholated) cigarettes. (Cigarettes are not provided by the study sponsor.)
Study: NCT04599270

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PREVENTURE Program
Description: Adolescents will be follow PREVENTURE program (2 session of 90 min).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine care
Description: Adolescents will be follow routine care
Study: NCT05013918

Intervention type: OTHER
Intervention: Observational study
Description: No intervention
Study: NCT06014931

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telemedicine ICU Recovery Clinic Visit
Description: Multidisciplinary clinic visit that encompasses a medical examination, medication management, neuropsychological exam with focused psychotherapy, case management, and patient-centered consultation.
Study: NCT05708781

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Core strengthening exercise
Description: 1. Isolated lumbar stabilization muscle training:~2. Bridge track:~3. Dead bug track:~4. Quadruped Track:~5. Supine Track:~6. Side-support Track:~7. Prone Track:~8. Standing Track:

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: intensive dynamic back exercise
Description: 1. Trunk lifting Prone on a couch, hips at the edge, upper part of the body free but supported by the hands against the floor. Strap fixation over the calves. With hands on the forehead, the trunk is lifted to the greatest possible extension in hips and spine. If necessary, starting with support from physical therapist. During pauses a chair in front of the couch supports the patient.~2. Leg lifting Standing by the end of the couch, leaning over to a prone position with the hips against the edge in 90 degree flexion, knees 45 degree and feet on the floor. Strap fixation over the chest. Straps around knees to keep legs together. Both legs are straightened and lifted to the greatest possible extension in hips and spine. Again support from physical therapist is necessary.~3. Pull to neck Sitting on a tool with the arms straight and abducted over the head and hands grasping a weight lever. Against sub-maximal resistance the lever is pulled behind neck and shoulders.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control group
Description: Hot Pack was given for twenty minutes, slow sustained stretching exercises ( 20 second hold, 10- second relaxation) were given, and isometric exercise of the back((10 repetitions of two sets with 10 seconds hold) alternate days for six weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Hot Pack was given for twenty minutes, slow sustained stretching exercises ( 20 second hold, 10- second relaxation) were given, and isometric exercise of the back((10 repetitions of two sets with 10 seconds hold) alternate days for six weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control group
Description: Hot Pack was given for twenty minutes, slow sustained stretching exercises ( 20 second hold, 10- second relaxation) were given, and isometric exercise of the back((10 repetitions of two sets with 10 seconds hold) alternate days for six weeks.
Study: NCT04926207

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity Breaks Intervention
Description: Participants will be asked to walk on a treadmill for 3 min at a moderate intensity (55% of heart rate reserve) at an increasing speed and incline to reach and maintain their target heart rate.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Talking Breaks Control
Description: Every 30 min a researcher will start a brief conversation with a participant based on a pre-selected topic, which will change with each break. Topics are standardized across participants and include, for example, pollution, smart clothes, and hydration. A presentation will be followed by questions and answers. The break will last 3 min.
Study: NCT06456125

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: amber SEL-P Peripheral Liquid Embolic System
Description: Transcatheter arterial or venous embolization with the liquid embolic agent amber SEL-P embolization across seven different indications for peripheral embolization.
Study: NCT04900337

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMOR 18 Powder & Inhalation
Description: AMOR Inhalation x 3 times a day, via Circulaire® II AMOR Powder x 4 times a day, sublingual

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Inhalation x 3 times a day, via Circulaire® II Placebo Powder x 4 times a day, sublingual
Study: NCT05399381

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial alternating current stimulation (tACS)
Description: Non-invasive, multi-electrode transcranial alternating current stimulation (tACS) over frontal and parietal brain areas.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial alternating current stimulation (tACS)
Description: Non-invasive, multi-electrode transcranial alternating current stimulation (tACS) over frontal and parietal brain areas.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial alternating current stimulation (tACS)
Description: Non-invasive, multi-electrode transcranial alternating current stimulation (tACS) over frontal and parietal brain areas.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial alternating current stimulation (tACS)
Description: Non-invasive, multi-electrode transcranial alternating current stimulation (tACS) over frontal and parietal brain areas.
Study: NCT05267899

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WGI-0301
Description: WGI-0301 is a lipid nanoparticle preparation of Archexin® for the treatment of advanced solid tumors.
Study: NCT05706610

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored Program
Description: Participants in the tailored program will participate in 4 sessions with a coach, 1 every other week. During these sessions, the AYA will work with their coach to identify a barrier to adherence to target and create an action plan using evidence-based behavior change techniques to address this barrier. In between sessions (on alternating weeks), the coach will check-in with a text including a reminder about the action plan and a calendar of the AYA's eCAP adherence data.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Feedback Program
Description: Participants in the Feedback Program will receive weekly text messages including: a calendar depicting their weekly adherence (per eCAP data) and guidance for requesting additional support as desired.
Study: NCT05533463

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-4642
Description: HRS-4642 will be administrated per dose level in which the patients are assigned.
Study: NCT05978076

Intervention type: OTHER
Intervention: data collection
Description: data collection : mechanism of injury, associated injury, length of stay, maximal lipase level, nutritional care and local complications.
Study: NCT05825924

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: E-Cigarette
Description: E-cigarettes have been designed to resemble tobacco cigarettes. They include an aerosol generator, sensor, battery and storage area for liquid. They are either disposable or rechargeable. According to a study, e-cigarettes can deliver an average of 1.3 mg (range 0.4 to 2.6 mg) of nicotine from 15 puffs. Average Cmax after e-cigarette use is recorded as 8.4 ng/mL and Tmax achieved between 2 to 5 minutes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine patch
Description: The nicotine patches are applied on the skin and nicotine is delivered at a steady rate. After administration, the peak blood levels are achieved within 6-10 hours. The levels remain constant, reducing by 25-40% with use of patches once daily. The patch is typically administered every 24 hours for no longer than 12 weeks. The dose of the patches is often determined by daily cigarette consumption and level of addiction.
Study: NCT05133947

Intervention type: OTHER
Intervention: Non interventional
Description: Non interventional
Study: NCT04652375

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Albumin Solution
Description: Participants will receive Albumin solution for fluid resuscitation post-surgery.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lactated Ringer's Solution
Description: Participants will receive Lactated Ringer's solution for fluid resuscitation post-surgery.
Study: NCT06024837

Intervention type: OTHER
Intervention: CT Images
Description: Analysis of CT images of peritoneal and/or liver metastases from colorectal cancer